German biotech BioNTech on Monday highlighted compelling preliminary data from a clinical trial evaluating a new mRNA-based cancer therapy, an early indication the technology behind some of the most effective Covid-19 vaccines could potentially unlock new treatments for cancer as well as target other infectious diseases.
